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PREFACE
A memorandum has been signed between the Centers for Disease Control, National Institute 
for Occupational Safety and Health (NIOSH), USA, and the Nordic Expert Group for 
Documentation of Occupational Exposure Limits (NEG). The purpose of the memorandum 
is to exchange information and expertise in the area of occupational safety and health. One 
product of this agreement is the development of documents to provide a scientific basis for 
establishing recommended occupational exposure limits. The exposure limits will be 
developed separately by each country according to the different national policies.
This document on the health effects of occupational exposure to ethyl ether is the second 
product of that agreement. The document was written by Björn Arvidson, Dr. Med Sc 
(Department of Occupational Medicine, University Hospital, Uppsala and Swedish National 
Institute of Occupational Health, Solna), and was reviewed by NEG and the Division of 
Standards Development and Technology Transfer (DSDTT), NIOSH.
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1 INTRODUCTION
Ethyl ether is a colorless, highly volatile, mobile liquid with a characteristic pungent odor. 
Ethyl ether is a serious fire hazard, as its vapor readily forms explosive mixtures with air and 
oxygen. It is miscible with the lower aliphatic alcohols, benzene, chloroform, petroleum ether, 
other fat solvents, and many oils. The primary physiologic effect of ethyl ether is general 
anesthesia.
2 PHYSICAL AND CHEMICAL PROPERTIES*
Chemical name:
CAS number:
Synonyms:
Molecular formula:
Structural formula:
Molecular weight:
Specific gravity at 20°C:
Boiling point (101.3 kPa):
Melting point:
Vapor pressure (20°C):
Saturation concentration (20°C, 101.3 kPa): 
Flash point:
Ethyl ether 
60-29-7
ether, diethyl ether, ethoxyethane, 
diethyloxide, ethyl oxide,
1, l'-oxybisethane
c 4h 10o
H H H H
H - C - C - O - C - C - H  
H H H H
74.12
0.7146
34.6°C
-116.3°C
58.5 kPa
57.75% (1,778,677 mg/m3)
-45°C
Distribution coefficient blood/gas: 12.1
Distribution coefficient oil/gas: 65
* Data taken from reference numbers 2, 3 ,7 , 8, 28 ,44 ,72 ,151 .
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Solubility in water at 20°C: 6.9% by wt.
Viscosity at 20°C: 0.00233 poise
Conversion factors (20°C, 101.3 kPa): 1 ppm = 3.08 mg/m3 
1 mg/m3 " 0.325 ppm
Ethyl ether usually starts to oxidize soon after distillation, and ether peroxides, acetaldehyde 
and acetic acid are formed. Ether peroxide is less volatile than ethyl ether and tends to 
concentrate during evaporation or distillation. Ether peroxides, when concentrated, are a 
serious detonation hazard. Ethyl ether can be tested for the presence of peroxides by shaking 
10 ml of ether for one min with 1 ml of a freshly prepared 10% aqueous solution of potassium 
iodide in a 25-ml, glass-stoppered cylinder of colorless glass, protected from light. Appearance 
of a yellow color indicates peroxides (53). Other rapid tests for detecting peroxides in liquids are 
also available (53). Peroxides can be removed by distillation or by passage through an alumina 
column. If activated alumina is used, the ether is also dried in the process (53). Ferrous sulfate 
(30% solution in water) can be used in the proportion of 1 lb (0.4536 kg) to each 30 U.S. 
gallons (113.51) of ethyl ether to extract and to destroy peroxides (7).
Factors which delay decomposition of ethyl ether are absence of light, storage in a cool place, 
storage in copper tanks, or contact with a copper screen. Copper and certain other metals, 
particularly iron and mercury, prevent the oxidation of ethyl ether since they are oxidized 
preferentially and consume the oxygen which is combined with ethyl ether (3). Ethyl ether 
should be stored in the original metal cans rather than in glass bottles. Very dry ethyl ether 
undergoes oxidation much more readily than ethyl ether containing a few tenths of a percent 
of water (7).
Ethyl ether is produced on a large scale by dehydration of ethanol or by hydration of ethylene, 
both processes being carried out in the presence of sulfuric acid (3, 28, 80, 151). Ethyl ether 
has a wide range of uses in the chemical industry. It is a good solvent for fats, oils, dyes, gums, 
resins, raw rubber, smokeless powder, perfumes, and nitrocellulose. Ethyl ether is also used 
in the manufacture of photographic films and pharmaceuticals, and as a reaction and extraction 
medium in the chemical industry. In addition, ethyl ether is used as an inhalation anesthetic 
in surgery, a refrigerant, in diesel fuels, in dry cleaning, and as a starting fuel for engines (8, 
28,31,80,136). Smith and Zenz (1988) reported an annual production of ethyl ether in excess 
of 125 million tons per year in the United States.
According to the Swedish Products Register at the National Chemical Inspectorate, ethyl ether 
was a constituent in 43 chemical products present on the Swedish market in August 1991. The 
estimated annual use in Sweden was 40-370 metric tons.
3 USES AND OCCURRENCE
3.1 Uses
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Ethyl ether is commercially available in different grades. Depending on the consumer and 
use, specifications vary. In many instances the ether has to meet a specific test which is written 
in the specification (e.g., it may be important that the ether is free from alcohol and aldehyde, 
or completely anhydrous). The technical concentrated ether contains very small amounts of 
alcohol, water, aldehydes, peroxides, and other impurities such as sulfuric acid, sulfur dioxide, 
mercaptans, and ethyl esters (3, 28, 35, 80). Some doubt exists as to whether or not these 
impurities as found in ethyl ether are toxic to man. In dogs, concentrations of aldehyde up to 
0.5% and mercaptans up to 1% produced no significant effects. Ether peroxides in a 
concentration of 0.3% had no effect whereas 0.5% caused a fall in blood pressure and 
respiratory difficulties. Ethyl sulfide in 1 % concentration caused gastroenteritis (23). Ethyl 
ether containing impurities produced anesthesia in mice more slowly than pure ethyl ether 
(84).
The more refined grades of ethyl ether, such as anesthetic ether, are obtained from technical 
ether by redistillation and dehydration followed by alkali or charcoal treatment (80).
3.2 Air Concentrations in the Working Environment
Hirsch and Kappus (70) published the first quantitative data on the concentration of inhalation 
anesthetic agents in operating room air in 1929. The levels of ethyl ether in several operating 
rooms during surgical procedures were measured with use of a combustion method. Ethyl 
ether levels ranged from 10 to 100 ppm (31 to 308 mg/m3) before any attempt to remove the 
waste ethyl ether vapor. The concentration of ethyl ether in several operating rooms decreased 
by 34 to 72% after use of a crude scavenging system, consisting of a vacuum cleaner and a 
large funnel.
Grigoriew (56), cited by Hayhursth (68), investigated air levels of ethyl ether in two Russian 
factories manufacturing smokeless powder. The concentrations of ethyl ether in air varied 
depending on season, temperature of the workroom, apparatus and other factors. In one 
of the factories, the minimum concentration of ethyl ether in air was reported to be 0.08 vol% 
(2,464 mg/m3) and in the other factory 0.007 vol% (215 mg/m3). The maximum values were 
21.18 vol% (652,344 mg/m3) and 2.7 vol% (83,160 mg/m3), respectively.
To prevent pollution by anesthetic gases in operating rooms, the Hospital Engineering 
Cooperative Groups of Denmark made recommendations in 1974 (146). The recommended 
highest permissible average concentration in the breathing zones of anesthesia personnel for 
ethyl ether was 3 ppm (9 mg/m3).
Air concentrations of ethyl ether were measured in the laboratory of a brewing company in 
Illinois, USA (154). Ethyl ether was used in an extraction procedure to determine the fat 
content in com. Environmental monitoring was conducted using two methods; (1) a direct 
reading instrument, and (2) personal and area sampling to determine the integrated average 
exposures over the work shift. All results for the personal and area samples were less 
than 1 ppm. Measurements with the direct reading instrument showed peak concentrations up 
to 1,000 ppm (3,080 mg/m3) around the cork gaskets and pressure release valves on the
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extraction apparatus. However, the vapors were released inside a plexiglass enclosure where 
they were properly exhausted.
Personal breathing zone and area samples were taken in an analytical laboratory using solvents 
in the preparation of soil and water samples (155). The values for ethyl ether were below the 
limit of quantitation (0.03 mg/sample).
The employee’s exposure to xylene, ethyl ether, and other vapors was evaluated in the 
cytology, hormone, and histology laboratories in a hospital in Missouri, USA (156). Breathing 
zone samples were taken on most of the workers with emphasis on those receiving the highest 
exposures. The concentration of ethyl ether in air varied between 2.6 and 186.6 mg/m3.
Environmental samples from an army ammunition plant in Virginia, USA, showed that the 
ethyl ether concentrations ranged from 90 to 712 ppm (277 to 2,193 mg/m3) (157).
3.3 Analytical Methods for Ethyl Ether in Air and Body Tissues
3.3.1 Direct Field Methods
Analysis of ethyl-ether-contaminated air in the work area may be done by means of a 
commercially available combustible gas indicator. Direct reading detector tubes are also 
available (8, 92).
3.3.2 Laboratory Methods
An air sampling technique for diethyl ether has been proposed by NIOSH (109). A known 
volume of air is drawn through a charcoal tube at a flow rate of 0.01 to 0.2 1/min. The charcoal 
in the tube is transferred to a small sample container and ethyl ether is desorbed with ethyl 
acetate. An aliquot of the desorbed sample is then injected into a gas chromatograph and the 
area of the resulting peak is determined and compared with standards. Advantages with this 
method is a small, portable sampling device and minimal interferences which can be eliminated 
by altering chromatographic conditions. A disadvantage is that the upper limit of the range 
of the method depends on the adsorptive capacity of the charcoal tube. In addition, the 
precision of the method is limited by the reproducibility of the pressure drop across the tubes.
Blood and tissue levels of ethyl ether can be analyzed by infrared analysis. This method was 
originally devised by Stewart et al. (144) and was used, with a slight modification, by 
Chenoweth et al. (33) for measuring blood and tissue levels of ethyl ether and other anesthetics 
in dogs. This method is also applicable to air analysis (8, 31).
Ethyl ether in blood and urine can be analyzed by gas chromatography. The specimen is 
injected directly into a gas chromatograph equipped with a flame-ionization detector and a 
molecular sieve column. Specimens should be stored at 4°C and analyzed as soon as possible. 
Breath samples may be analyzed by direct injection of 1-2 ml, using as standards suitably
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prepared dilutions of ethyl ether in air. Calculation is based on a standard curve of peak height 
versus concentration of the standards (17).
Ethyl ether in air may be analyzed by passing the air through a fritted glass bubbler for 
reaction of the ethyl ether with acidic potassium dichromate and subsequent iodometric 
determination (133). A modification of this method has also been used for determination of 
ethyl ether in blood (6, 117).
3.4 Biological Monitoring
Tests for exposure may include expired breath for unmetabolized ethyl ether and blood for 
ethyl ether content (8). Blood concentrations of ethyl ether have been found to correlate with 
the degree of ethyl ether exposure and the extent of intoxication. According to Baselt (17), 
the concentration of ethyl ether in blood should not exceed a level of about 20 mg/1 in 
asymptomatic workers. Gas chromatography can be used for determinations of ethyl ether in 
blood, urine, and breath samples (17). Infrared analysis can be used for detection of ethyl 
ether in breath and body fluids (8).
4 DISTRIBUTION AND METABOLISM
4.1 Uptake
4.1.1 Uptake by Inhalation
After inhalation, ethyl ether is rapidly transferred from alveoli to blood. The normal alveolar 
membrane poses no barrier to the transfer of ethyl ether in either direction. The blood/gas 
distribution coefficient of ethyl ether is high— 12.1. For oil/gas, the distribution coefficient 
is 65 (44). The more soluble an anesthetic is in blood, the more of it must be dissolved in 
blood to raise its partial pressure there appreciably. Induction of ethyl ether anesthesia is 
therefore slow. To achieve deep anesthesia with ethyl ether in medical practice takes 15-25 
min (35) (the concentration of ethyl ether used for the induction of anesthesia is usually 10 to 
15 vol% or 308,000 to 462,000 mg/m3).
4.1.2 Uptake from the Gastrointestinal Tract
No studies on the uptake of ethyl ether after peroral administration were found. According to 
Hayhursth (68), absorption of ether from the stomach and rectum is very prompt and may be 
used for anesthesia.
4.1.3 Uptake through the Skin
Smyth etal. (138) investigated the penetration of rabbit skin for different chemical compounds. 
The fur was removed from the trunk by clipping, and the dose was retained beneath an 
impervious plastic film. Doses over 20 ml/kg b.w. could not be retained in contact with the 
skin. For ethyl ether, the single dermal penetration LD50 was greater than 20 ml/kg b.w.
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No data were found on the extent of uptake of ethyl ether through undamaged skin in humans. 
A case report described a 14-year-old boy who applied ethyl ether to his scalp under plastic 
occlusion to treat a seborrheic dermatitis. The boy was found dead and elevated but nonfatal 
concentrations of ethyl ether were found in the various postmortem tissues subjected to 
toxicological analysis. The authors conclusion was that the boy died from intoxication of 
resorbed ethyl ether. The authors interpreted the sublethal ethyl ether concentrations found in 
various tissues as probably incorrect due to ethyl ether’s high volatility (29).
4.2 Distribution
The concentration of ethyl ether in various tissues of rats during ethyl ether narcosis was 
investigated by Dybing and Dybing (41, 42) and Dybing and Skovlund (43). The animals 
inhaled ethyl ether at a concentration of 300,000 mg/m3 (approximately 9 vol%). The 
concentration of ethyl ether in arterial blood rose rapidly during the first min and then more 
slowly until a diffusion equilibrium with the ethyl ether concentration in alveolar air was 
attained. The concentration of ethyl ether in the brain rose initially with the same rapidity as 
in the arterial blood. From about 5 min and onwards, the concentration of ethyl ether in the 
brain is constantly greater than the arterial concentration, reflecting the greater solubility of 
ethyl ether in brain tissue. The ethyl ether concentration in muscle was much lower than in 
the arterial blood or brain in the early stages of anesthesia (41, 42). Ethyl ether was taken up 
rapidly by omental and perirenal fat, and after a few min, the concentration of ethyl ether in 
fatty tissue was the same as in blood. The maximum concentration of ethyl ether in fat was 
reached after 1/2 to 1 hr. After continuous administration of ethyl ether for 1 hr, the mean 
concentration of ethyl ether in blood, omental fat and perirenal fat was 1,270, 2,870 and 
2,140 mg/kg, respectively (43).
The distribution of 14C-ethyl ether in the mouse was investigated with use of low-temperature 
autoradiography (34). Ethyl ether was administered by inhalation for 10 min. When the 
animals were killed immediately after the inhalation period, the anesthetic was rather uniformly 
distributed throughout the body, although higher concentrations were found in the brain, 
kidney, liver, and brown fat. After 2 hr, most of the radioactivity had left the body, but the 
liver, kidneys, intestines, and nasal mucous membranes were still labelled. A quantitative 
analysis showed that in 15 min, the radioactivity in brown fat had reached its peak relative 
concentration, whereas the relative concentrations of radioactivity in liver and kidneys 
continued to increase until the termination of the 2-hr experimental period. At 2 hr, 3.6% of 
the administered dose was present in metabolized form in the liver and intestine. By that time, 
all liver radioactivity was nonvolatile.
The distribution of ethyl ether and four other volatile organic solvents in blood was investigated 
in rats. The animals were exposed to 500 ppm (1540 mg/m3) of ethyl ether for 2 hr. Forty-nine 
percent of ethyl ether in the blood was found in the red blood cells. When a solution of ethyl 
ether was added to human plasma and red blood cell (RBC) samples, a large fraction of ethyl 
ether was recovered from ammonium-sulphate-precipitated plasma proteins and hemoglobin. 
A small fraction of ethyl ether was recovered from plasma water and RBC water. The authors
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conclude that proteins, chiefly hemoglobin, are the major carriers of ethyl ether and other 
volatile organic solvents in blood (87).
4.3 Biotransformation
It has been estimated that about 8-10% of absorbed ethyl ether is metabolized in the body (55) 
whereas the remainder is excreted unchanged through the lungs. Ethyl ether is metabolized 
to ethanol and acetaldehyde by an inducible hepatic microsomal enzyme system, a cytochrome 
P450-containing monooxygenase system (32, 145). Ethanol and acetaldehyde are rapidly 
oxidized to acetate, and the acetate subsequently enters the 2-carbon pool of intermediary 
metabolism.
Van Dyke et al. (160) showed in rats that approximately 4% o f an intraperitoneally- 
administered dose (0.1 ml) of 14C-ethyl ether was recovered as exhaled 14C 0 2  during a 24-hr 
period, and 2% of the radioactivity was transformed into nonvolatile urinary products. Green 
and Cohen (55) reported that a portion of 14C-diethyl ether administered to mice by inhalation 
was rapidly transformed into fatty acids (palmitic, stearic, and oleic acids) and cholesterol, 
which were recovered from an ether extract of liver. Three other nonvolatile radioactive 
metabolites were tentatively identified as monoglycerides, diglycerides, and triglycerides.
Two hr after administation of ethyl ether by inhalation to mice, 3.6% of the administered dose 
was present in metabolized form in the liver and intestine. Thin-layer radiochromatography 
of extracts from the liver demonstrated four nonvolatile metabolites. The major metabolite 
was presumed to be a glucuronide of ether (34).
The hepatic microsomal oxidation of ethyl ether is catalyzed primarily by the cytochromes 
P450 (32). More recent investigations have implicated specific isoenzymes. Known in­
hibitors of isoenzyme HE1 strongly inhibited ether de-ethylation, and a monoclonal antibody 
to P450IIE1 had the same effect (24). A mixed-function oxidation known to be catalyzed by 
cytochrome P45013E1, the N-demethylation of dimethylnitrosamine, was inhibited by ethyl 
ether anesthesia (150). These findings all indicate that ethyl ether is oxidatively metabolized 
primarily by P450UE1 (24).
4.4 Elimination
The majority of inhaled ethyl ether is excreted unchanged through the lungs. In experiments 
on dogs, Haggard (61) reported that the recovery of ethyl ether in expired air was 79 to 92% 
(average for 12 dogs 87%). Onchi and Asao (112) attempted to recover inhaled ethyl ether 
from human patients and volunteers. They used a lower concentration of ethyl ether than 
Haggard and reported a recovery of 37 to 84% of the administered dose. It is estimated that 
only about 8-10% of the absorbed dose of ethyl ether is metabolized in the body (55). In rats 
given 0.1 ml of 14C-ethyl ether by intraperitoneal injection, about 4% of the administered 
dose was recovered as exhaled 14C02 and 2% was transformed into nonvolatile urinary 
products (160).
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The concentration of ethyl ether in brain, blood, and muscle was investigated in rats during 
ether elimination. When the rats had breathed 300,000 mg/m3 (approximately 9 vol%) 
of ethyl ether for 10 min, there was an abrupt fall of the concentration of ethyl ether in the 
brain and blood immediately after discontinuation of the inhalation. When the inhalation 
exposures were discontinued after 1 hr, the fall in the ether concentration in the brain and blood 
was slower (42). The elimination of ethyl ether from fatty tissue occurred slowly, and was 
practically finished after about 8 hr (43).
According to the experience of anesthesiologists, termination of anesthesia with soluble 
anesthetics like ethyl ether is slower in obese individuals than in those with a lean body mass. 
This might partly be due to partioning of the anesthetic agent into certain tissues (e.g., body 
fat) (25).
4.5 Mechanism of Ether Resistance in Drosophila Melanogaster
A few studies have been performed to elucidate the mechanism of ethyl ether resistance in 
certain strains of Drosophila melanogaster. A strain named Eth-29, was found to be resistant 
to ethyl ether and other volatile anesthetic agents like chloroform and halothane. Ethyl ether 
resistance for lethality was determined using mortality as an endpoint when flies were exposed 
to very high concentrations of ethyl ether (111). Ethyl ether resistance to anesthesia uses loss 
of avoidance reflex as an endpoint, and is an incompletely dominant or polygenic character 
(49). The resistance for ethyl ether anesthesia and for ethyl ether lethality was found to be 
controlled by different genetic systems.
In 18 strains of Drosophila melanogaster with different genetic characteristics, a wide 
variation in sensitivities to ethyl ether anesthesia, gamma-ray knock-down and gamma-ray 
lethality was demonstrated. There was no correlation between DNA-repair capacity and ethyl 
ether sensitivity or gamma-ray knock-down sensitivity, whereas strains deficient in excision 
repair were found to be sensitive to gamma-ray lethality. These findings indicate that lethality 
is caused by DNA damage, whereas the targets for ethyl ether anesthesia should be different, 
possibly being the membrane (50).
5 GENERAL TOXICOLOGY
5.1 Mechanism of Action
The mechanism of action by which general anesthetics, including ethyl ether, produce 
reversible loss of consciousness is still unclear. Anesthesia can be produced by a wide variety 
of chemical agents, ranging from inert rare gases to steroid molecules (128). This apparent 
lack of specificity, together with the observation that general anesthesia can be reversed by 
high pressure, poses a unique pharmacological problem (48). Most theories concern interac­
tion of anesthetics with either membrane lipids or hydrophobic regions of specific membrane- 
bound proteins (for reviews see 48, 63, 128). One hypothesis is that the anesthetic changes 
the function of an ion channel protein by modifying the conformation of the protein. Some
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investigators suggest that the GABA receptor may be the ion channel protein that is affected 
by inhalation anesthetic agents (25, 101). According to Halsey (63), the most appropriate 
concept for the mechanism of general anesthesia is a heterogenous site of anesthetic action, 
including both lipid and protein membrane components linked with the neuronal function.
5.1.1 Effects of Ethyl Ether on the Metabolism of Ethanol and Certain Drugs
Prolonged inhalation of ethyl ether has been shown to cause proliferation of the endoplasmic 
reticulum in liver cells and induction of drug-metabolizing enzymes (27, 127), whereas acute 
treatment with ethyl ether has been reported to inhibit drug metabolism. Ethyl ether is 
oxidatively metabolized in liver microsomes primarily by an ethanol-inducible cytochrome 
P450 (P450IIE1) (24). Ethyl ether can serve as a substrate for P450EII1 as well as a 
competitive inhibitor for the metabolism of other substrates (150). This mechanism underlies 
the inhibitory action of ethyl ether on the metabolism of ethanol (9, 71, 110), since the 
microsomal oxidation of ethanol is accomplished primarily by cytochrome P450EII1 (94). 
The metabolism of other substrates for cytochrome P450EH1 like N-nitrosodimethylamine 
(NDMA) and paracetamol is also inhibited by ethyl ether (10, 73, 79, 150, 152).
Rats given pentobarbital i.p. (25 mg/kg) and exposed to 3.6 vol% (110,880 mg/m3) ethyl ether 
vapor for 40 min had higher concentrations of pentobarbital in the liver, fat, brain, and plasma 
than did rats given the same dose of pentobarbital without ethyl ether exposure. Only the 
increases in liver and plasma pentobarbital concentrations were statistically significant, 
however. No difference was found in kidney pentobarbital levels (13). The influence of ethyl 
ether anesthesia on the metabolism of hexobarbital was investigated in rats. The experiments 
were carried out in a crossover design with a 1-week interval. Five rats received 50 mg/kg of 
sodium hexobarbital i.v. with and without a light ethyl ether anesthesia during the experiments. 
Ethyl ether was administered continuously by covering the nose of the animals with a flask 
containing an ethyl-ether-soaked cotton plug. The elimination half-life of hexobarbital 
increased by about 50% in rats exposed to ethyl ether (161).
The metabolism of diphenylhydantoin (DPH) in rats was inhibited by ethyl ether whereas 
urethane had no effect. Ethyl ether was administered either continously throughout the 3-hr 
experiment (three rats) or for 5 min prior to the drug administration to anesthetize the rats and 
then discontinued (six rats). Ethyl ether was administered by covering the nose with a beaker 
containing a cotton plug soaked with ethyl ether. Continous ethyl ether administration 
prolonged the DPH half-life 10-fold compared with urethane anesthesia, while brief ethyl ether 
anesthesia had a delayed inhibitory effect on DPH elimination for about 1 hr. The inihibitory 
action of ethyl ether on DPH metabolism was probably at the hydroxylation step (153).
5.1.2 Effects of Ethyl Ether on Protein Synthesis in Animals
Male Wistar rats were exposed to anesthetic doses of ethyl ether by inhalation for 10 min and 
were sacrificed 20 or 40 min after initiation of anesthesia. The concentration of ethyl ether in 
blood at the end of the experiment was 7.1 and 9.0 mM/1 (526 mg/1 and 667 mg/1), respectively. 
On the average, the rate of synthesis of liver proteins was reduced with 20% compared to a
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group receiving no anesthesia. A more pronounced inhibition of synthesis/secretion of plasma 
proteins was reported, approximately 70-80%  compared to animals either receiving 
no anesthesia or pentobarbital. Protein synthesis was measured by the incorporation of 
radioactively-labelled valine into liver and plasma proteins. It was suggested that this effect 
might be due to impaired function of endoplasmic membranes or of membranes belonging to 
the Golgi-secretory apparatus (19).
Ethyl ether inhibited protein synthesis also in isolated rat hepatocytes. Protein synthesis was 
measured as the incorporation of radioactively labelled valine into liver proteins. Concentra­
tions of ethyl ether of approximately 10,20, and 30 mM (741, 1,482 and 2,223 mg/1) caused 
27, 50, and 74% inhibition, respectively. In contrast to ethyl ether, pentobarbital reduced the 
synthesis of cell and medium proteins very little, while the opiate anesthetic fentanyl had no 
inhibitory effect (20).
Light ethyl ether anesthesia for 1-2 min did not affect the rate of protein synthesis measured 
in the mammary gland, liver, intestinal mucosa, and muscle of lactating rats using a flooding 
dose of 3H-phenylalanine that was injected intravenously. The fractional rates of protein 
synthesis were estimated from incorporation of 3H-phenylalanine into tissue proteins (131).
5.2 Acute Toxicity
5.2.1 Human Experience
5.2.1.1 Inhalation
Ethyl ether has been used since 1840 as an anesthetic agent with medical safety. There are 
few reports of death due to ethyl ether anesthesia in the literature. Campbell (30) did personal 
autopsies of 195 cases of death associated with anesthesia during a 30-month period from 
1957 to the middle of 1959. In four cases, ethyl ether was given as a factor causing or 
contributing to death. Postmortem ethyl ether concentrations in blood o f2,880 and 3,750 mg/1 
were observed in two surgical patients who died within 2.5 hr after cessation of ethyl ether 
administration.
Almost all of the reported human experience concerning the use of ethyl ether involves its use 
as an anesthetic agent. Industrial exposure has caused very few deaths or illnesses, and thus 
very few reports appear in the literature. One case of human death in industry due to acute 
inhalation of ethyl ether used in perfumery manufacture was reported by Hayhursth (68). The 
patient developed acute mania and died in uremic convulsions. Symptoms of acute overex­
posure after inhalation of large quantities of ethyl ether are drowsiness, vomiting, paleness of 
the face, lowering of the pulse and body temperature, irregular respiration, muscular relaxation, 
and excessive salivation (31, 47). Aftereffects of acute ethyl ether poisoning are vomiting, 
irritation in the tracheobronchial tree, headache, salivation, and depression or excitation (31). 
Treatment of overexposure to ethyl ether is symptomatic and no specific antidotes are known. 
Oxygen therapy may be used in cases of narcosis (7).
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5.2.1.2 Ingestion
Moeschlin (99) has estimated the lethal dose of ethyl ether after peroral intake to be about 
30 ml (21.4 g) or more. A lethal dose of 30-50 g ethyl ether after peroral intake was given 
by Geldmacher-v Mallinckrodt (52). A 1-year-old child who died o f peroral intake of an 
unknown amount of ethyl ether had a postmortem ethyl ether concentration in blood of 
2,360 mg/1 (123).
In ethyl ether addiction, tolerance develops and large daily quantities of ethyl ether may be 
ingested (16, 52). A daily intake of up to 180 g has been reported (52).
5.2.2 Animal Studies
5.2.2.1 Inhalation
Differences in the induction mixture and the duration of anesthesia may lead to different results 
for lethal concentrations of inhaled ethyl ether in animals (124). During a continuous exposure 
for 97 min, the lethal concentration of inhaled ether for mice was 133,400 mg/m3 or 4.4 vol% 
(86). When rapid induction and short duration of anesthesia was used, the concentration 
necessary to produce respiratory arrest in mice was 18 vol% (554,000 mg/m3) (103). The 
lethal concentrations for the rat, rabbit, and dog were 6.4, 10.6 and 7.16 to 19.25 vol%, 
respectively (139). The age of the animal has importance for susceptibility to inhaled ethyl 
ether. In rats, the median time to death (LT50) for neonates was 5 to 6.5 times greater than for 
adult rats and the mean concentration of ethyl ether in blood at the respective LT50 values was
2.5 to 3 times greater in neonatal rats than in adult rats (132).
5.2.2.2 Ingestion
The oral LD50 in 2-week-old, young adult (body weight 80-160 g) and adult (body weight 
300-470 g) Sprague-Dawley rats, were reported to be 2.3,2.4 and 1.7 ml/kg b.w., respectively 
(83). Smyth et al. (138) reported a single peroral LD50 for rats of 3.56 ml/kg.
5.3 Chronic Toxicity
Long-term exposure to low concentrations of ethyl ether vapor is found especially in the 
industries that work with nitrocellulose (e.g., in the manufacture of smokeless powder). 
Reported symptoms are loss of appetite, exhaustion, headache, sleepiness, dizziness, excita­
tion, and psychic disturbances (47). Blood samples from some individuals chronically 
exposed to ethyl ether vapor during the manufacture of smokeless powder showed 
polycythemia and leukocytosis (65).
Werthmann (168) described effects of chronic exposure to ethyl ether among surgeons and 
nurses working in an operation theatre. The concentration of ethyl ether in air in an unventi­
lated operation theatre during an operation was estimated at 22,000 mg/m3 (0.73 vol%). 
Among the symptoms were tiredness, headache, loss of appetite, irritability, and difficulties
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in concentrating. Blood samples showed an increase in the number of lymphocytes and 
eosinophils.
Humans generally refrain from drinking ethyl ether due to its irritating effects on mucous 
membranes. Repeated drinking has, however, taken place, sometimes intentionally to reach 
a state of euphoria, resulting in the development of the “ether habit.” The symptoms are similar 
to those of chronic alcoholism (28).
6 ORGAN EFFECTS
6.1 Skin, Mucous Membranes, and Eyes
Liquid ethyl ether is a mild skin irritant. Ethyl ether does not usually cause any damage if skin 
contact is of short duration. Repeated exposure of the skin to ethyl ether, however, causes 
cracking and drying due to defatting (31).
Topical application of ethyl ether has been used for treatment of herpes simplex labialis (60, 
116, 149). The basis for this treatment is that the infectivity of herpes simplex virus is 
eliminated after exposure to diethyl ether in vitro (76).
Ethyl ether causes conjunctival irritation in either liquid form or high concentrations in the 
air. Prolonged exposure of the cornea to high concentrations of ethyl ether vapor, as employed 
in general anesthesia, causes superficial damage to the corneal epithelium. The recovery is 
usually prompt (54). The eye injury caused by ethyl ether instillation was tested in a standard 
manner on rabbit eyes. Ethyl ether caused slight reversible injury, graded 2 on a scale of 1 to 
10 (138).
6.2 Respiratory System
Ethyl ether vapor is an irritant to the mucous membranes of the nose and tracheobronchial tree 
(35, 40). Nelson et al. (106) studied the irritating effects of ethyl ether vapor on humans. 
Complaints of nasal irritation started at 200 ppm (616 mg/m3), and 300 ppm (924 mg/m3) was 
considered objectionable as a working atmosphere. Ethyl ether increases the amount of 
bronchial secretion but also has a dilating effect on the bronchi and bronchioles, which makes 
it a useful anesthetic agent for patients with asthma and bronchiolar spasm (35). Ethyl ether 
increases the rate of respiration by stimulating the nerve endings in the bronchial tree, and in 
this way reflexly excites the respiratory centre. Ethyl ether may also sensitize the barorecep- 
tors. With increasing depth of anesthesia, the paralysant action of ethyl ether causes a steady 
decline in min volume until apnoea finally supervenes (35).
Ethyl ether has been used in the treatment of severe attacks of acute asthma (125). The 
mechanism of action of ethyl ether in asthma is unclear. It has been suggested that ethyl ether 
anesthesia causes bronchodilation through release of adrenal catecholamines, which leads to
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relaxation of bronchial smooth muscle through beta-adrenergic stimulation (11). A direct 
relaxing effect of smooth muscle has also been suggested (22). Ethyl ether given intravenously 
in baboons had no effect on bronchoconstriction caused by intravenous acetylcholine, his­
tamine or phenylephrine administered either alone or in combination with propranolol (104).
6.3 Liver
Rosenthal and Bourne (126) investigated the effect of anesthetics on hepatic function in dogs. 
Half an hour of ethyl ether anesthesia caused slight impairment of liver function as measured 
with the bromsulphalein test. Two hr of ethyl ether anesthesia caused an average dye retention 
of 14% 15 min after injection (controls 0%). Recovery was usually complete in 24 hr.
A study of liver function was performed on 100 patients selected at random from those 
undergoing abdominal surgery. Fifty patients received anesthesia with halothane as the 
principal agent, and 50 received anesthesia with ethyl ether. After ethyl ether administration, 
a significant increase occurred in SGOT (serum glutamic-oxaloacetic transaminase) activity. 
When the two groups were compared, a significantly greater increase in alkaline phosphatase 
was found after ethyl ether anesthesia, whereas a significantly greater elevation of serum 
unconjugated bilirubin occurred after use of halothane (37).
Ethyl ether anesthesia has been shown to cause a transient reduction of hepatic uridine 
diphosphoglucuronic acid (UDPGA) levels in rats (45, 166). UDPGA is necessary for 
glucuronidation, an important biotransformation pathway in the elimination of endogenous 
and exogenous compounds. The glucuronidation of bilirubin was decreased in rats by ethyl 
ether anesthesia (39).
Ethyl ether is metabolized to acetaldehyde by hepatic microsomal enzymes. Long-term ethyl 
ether treatment of rats leads to induction of hepatic microsomal enzymes and to proliferation 
of smooth endoplasmic reticulum (127).
6.4 Kidneys
Albuminuria from tubular irritation has been reported to occur in about one-fourth of patients 
anesthetized with ethyl ether (68).
Chronic exposure to ethyl ether during the manufacture of smokeless powder has been claimed 
to cause occasional cases of nephritis (28, 65, 68), but this effect has since been questioned. 
Hamilton (64) described a man who had worked continuously for 7 years and intermittently 
for 5 years in a smokeless powder factory, and who developed a severe chronic interstitial 
nephritis verified at autopsy.
Ethyl ether has been used for dissolution of an obstructed Foley catheter balloon. The use of 
ethyl ether for this purpose has occasionally resulted in a chemical cystitis with permanent 
damage to the urinary bladder (51, 91, 105).
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6.5 Centra! Nervous System
Acute exposure of humans to high concentrations of ethyl ether vapor causes initial excitement 
followed by narcosis and respiratory depression. The different stages of ethyl ether anesthesia 
have been described in detail and are given in Table 1. The approximate blood and alveolar 
levels of ethyl ether in relation to the depth of anesthesia are given in Table 2.
Long-term exposure to low concentrations of ethyl ether vapor in industry, for example during 
the manufacture of smokeless powder, has been reported to cause various symptoms from the 
central nervous system such as sleepiness, dizziness, excitation, headache and psychic dis­
turbances (47). Surgeons and nurses exposed for long periods of time to ethyl ether in the 
operation theatre complained of tiredness, headache, loss of appetite, irritability and difficul­
ties in concentrating (168).
Ethyl ether has been reported to have complex effects on learning and memory in experimental 
studies in mice. Ethyl ether, like strychnine, appears to be a modulator of learning and memory 
(96). Some investigators have described retrograde amnesia after exposure to ethyl ether, but 
due to differences in methodology, the amnestic effects of ethyl ether have not been found 
consistently (167). Abt et al. (1) studied one-trial conditioning in mice and concluded that 
ethyl ether could produce amnesia, whereas other investigators have found that ethyl ether 
enhances learning (170, 171). Alpem and Kimble (4) found that ethyl ether causes retrograde 
amnesia in mice when ethyl ether was administered at an elevated temperature, but not at room 
temperature. Van Buskirk and McGaugh (159) reported that ethyl ether (7 ml in a 500 ml jar) 
administered to mice immediately after training but before electroconvulsive shock (ECS) 
provided complete protection from the amnestic effects of ECS. The mechanism behind the 
amnesia-attenuating effect of ethyl ether is obscure.
Ethyl ether causes cerebrovascular dilatation at twice the minimum anesthetic concentration 
(the minimum anesthetic concentration is the concentration at which 50% of the subjects move 
in response to a surgical stimulus) (172). The cerebral blood flow (CBF), cerebral metabolic 
rate for oxygen (CMRO2), and cerebrovascular resistance (CVR) were measured in two groups 
of monkeys inhaling 2 vol% (61,600 mg/m3) and 5 vol% (154,000 mg/m3) ethyl ether in air. 
CVR fell by 30% when ethyl ether concentration was increased from 2 to 5% whereas CBF 
and CMRO2 were unaltered. The conclusion of this study was that the effect of ethyl ether 
on CVR probably reflects a complex interaction of a number of factors such as alterations in 
alfa-adrenergic tone associated with changes in plasma epinephrine levels, alterations in 
vasoactive metabolites and alterations in beta-adrenergic receptor activity (75).
The effects of ethyl ether on the morphology of the blood-brain barrier within the optic tectum 
was investigated in hatching chick embryos and young chickens. Ethyl ether was administered 
on a small compress of surgical gauze covering the chick beak until anesthesia was reached 
(1 -3 min). Horseradish peroxidase was used as a marker of vascular permeability. Ethyl ether 
anesthesia was reported to produce extravasation of HRP by opening the tight interendothelial 
junctions. Areas of tracer extravasation were more numerous in the tecta of hatching embryos 
than in young chickens (108).
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Richards and White (122) investigated the effect of volatile anesthetics (ethyl ether, halothane, 
methoxyflurane and trichloroethylene) on the synaptic transmissions in the dentate gyrus. The 
experiments were performed in vitro using a preparation of the dentate gyrus of the hippocam­
pus in guinea pigs. Ethyl ether was applied to slices of the dentate gyrus in the gas phase by 
mixing ethyl ether with the O2JCO2 gas mixture that superfused the upper surface of the slice. 
All four anesthetics depressed synaptic transmission in the dentate gyrus. The mechanism 
behind this effect was interpreted to be either a reduction of transmitter release, or a decrease 
in the sensitivity of the postsynaptic membrane to released transmitter, or both effects together.
EEG monitoring in animals during anesthesia with ethyl ether has shown that ethyl ether 
reduces neuronal excitability (93,147). The depressive effect of increasing concentrations of 
ethyl ether on the central nervous system is also evident from Table 1.
Table 1.—The stages o f ethyl ether anesthesia*
Respiration Pupils Reflex
Stage Rhythm Volume Size Position depression
Stage I 
(analgesia)
Irregular Small Small Divergent Nil
Stage II 
(delirium)
Irregular Large Large Divergent Eyelash
eyelid
Stage III 
(surgical 
anesthesia)
Plane I Regular Large Small Divergent Vomiting
conjunctival,
pharyngeal
Plane II Regular Medium 1/2 dilated Fixed
centrally
Corneal
Plane III Regular, pause 
after expiration
Small 3/4 dilated Fixed
centrally
Laryngeal,
peritoneal
Plane IV Jerky,
irregular
Small Fully dilated Fixed
centrally
Anal
sphincter,
carinal
Stage IV 
(medullary 
compression)
Apnea
‘Adapted from references 35 and 59.
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6.6 Peripheral Nervous System
Larrabee and Pasternak (90) studied the concentrations of various anesthetics required to block 
synaptic excitation of sympathetic ganglion cells and compared that to concentrations neces­
sary to block conduction along sympathetic nerve fibers. The experiments were performed 
on in vitro preparations from cats, rats, and rabbits. Ethyl ether depressed synaptic transmis­
sion through a sympathetic ganglion in a concentration similar to that assumed to exist in the 
blood during surgical anesthesia. The conduction along autonomic fibers of different types 
(A, B, and C) was blocked by ethyl ether, but synaptic transmission was depressed more readily 
than conduction along any type of axon.
Ethyl ether and halothane were found to affect the kinetics of sodium and potassium current 
in vitro in the crayfish giant axon. Both anesthetics caused a reversible, dose-dependent 
speeding up of sodium current inactivation at all membrane potentials. The activation of 
potassium currents was faster with ethyl ether present, but there was no change in the voltage 
dependence of steady-state potassium currents. A theory was proposed that the effects on 
sodium and potassium channel gating processes was due to ei ther an effect on the state of the 
lipids surrounding the channels, or a direct effect on the protein part of the channels (18).
A bath concentration of 100-300 mM (7,412-22,236 mg/1) ethyl ether blocked the conduction 
of single action potentials in the bifurcating axon of the lobster deep extensor muscles (58). 
In frog sciatic nerve, 300 mM (22,236 mg/1) ethyl ether was needed to depress single axon 
sodium currents (81). Significant depression of mammalian B and C fibers was produced by 
77 mM (5,707 mg/1) ethyl ether (90).
6.7 Muscle
Ethyl ether causes muscle relaxation by its depressing effect on the central nervous system 
(CNS) and by affecting neuromuscular transmission and the muscle itself. The mechanism of 
neuromuscular blocking action of ethyl ether seems to be similar to, but not identical with that 
of d-tubocurarine (35, 77). When these two drugs are used in the same patient, an additive 
effect results from their synergism (35). The neuromuscular block produced by ethyl ether 
was not effectively antagonized by edrophonium or succinylcholine (77) whereas neostigmine 
has been reported to reverse the effect of ethyl ether on the motor end-plate (57). The reduction 
of muscle contractility caused by ethyl ether might be due to a pharmacological effect at the 
level of the sarcoplasmic reticulum (82, 129).
6.8 Gastrointestinal Tract
Salivary and gastric secretions are increased during light ethyl ether anesthesia, but are 
decreased during deep anesthesia. Bowel movement is decreased due to stimulation of dilator 
fibers and to depression of plain muscle (162). Nausea and vomiting are common after 
anesthesia with ethyl ether. Ethyl ether stimulates the vomiting center in the medulla, and 
ethyl ether is absorbed in saliva and passes to the stomach where it irritates the mucosa (35).
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The incidence of postoperative nausea varies with the length of operation and depth of 
anesthesia (162).
6.9 Circulatory System
Ethyl ether vapor depresses myocardial activity if added to the circulation in a heart-lung 
preparation (119). Ethyl ether anesthesia causes increased sympathetic nervous activity in the 
dog and man (98) and the plasma levels of noradrenaline increase with increasing depth of 
ethyl ether anesthesia (21). Skovsted and Price (134) postulated that the increase in sym­
pathetic preganglionic activity caused by ethyl ether anesthesia in cats was due to a central 
action on the medullary vasomotor center or on spinal vasomotor neurons. The direct 
myocardial depressant action of ethyl ether seen in the isolated heart preparation is antagonized 
by the positive inotrope effect of adrenaline and noradrenaline released during ethyl ether 
anesthesia (26). Ethyl ether seems to block parasympathetic activity in normal man (118). 
Ethyl ether anesthesia produces remarkably small alterations in blood pressure and pulse rate 
and rarely leads to cardiac arrythmias (35).
In a study in rats, the effects of ethyl ether anesthesia on whole-body hemodynamics and organ 
blood flow was measured using microspheres. Anesthesia was induced using a bell jar 
containing a gauze pad moistened with ethyl ether, and the animals were maintained between 
stage II and stage HI of anesthesia. Ethyl ether anesthesia initially decreased arterial pressure 
and the total peripheral resistance, whereas the cardiac index was increased. Later, the cardiac 
index returned to normal and there was an increase in total peripheral resistance index. The 
blood flow to the spleen, stomach, intestine, kidneys, and colon decreased during anesthesia 
whereas the blood flow to the brain and heart increased (141).
6.10 Hematological System
Anesthetic agents may have both direct and hormone-mediated effects on the leukocytes. 
After ethyl ether anesthesia in man, a postoperative leukocytosis has been reported which is 
related to the sympathomimetic effects of ethyl ether (164).
Blood samples from workers chronically exposed to ethyl ether fumes in the manufacture of 
smokeless powder showed in some individuals polycythemia and increased number of 
leukocytes (65).
The immediate effects of ethyl ether upon some of the blood components was investigated in 
cats. The animals (12 cats) were placed in a box and ethyl ether was then administered by 
cone. Blood samples were taken immediately thereafter, usually not more than 10 to 15 min 
after anesthesia had begun. Ethyl ether produced an immediate increase in the hematocrit 
value, leukocytes, lymphocytes and polymorphonuclear (PMN) cells of the blood of cats 
drawn from either the heart or ear. There was no change in the relative proportion of 
lymphocytes and PMN cells (137).
17
Ethyl ether anesthesia caused a statistically significant increase in prothrombin time and a 
decrease in bleeding time, coagulation time and platelet count in 25 healthy individuals (age 
16-40 years) undergoing elective surgery. Halothane and trichloroethylene anesthesia did not 
affect coagulation parameters (14).
6.11 Endocrine Organs
6.11.1 Man
Anesthesia and noxious surgical stimulation are accompanied by profound changes in en­
docrine function. Anesthesia is generally considered to affect endocrine responses less than 
surgery, but certain endocrine effects produced by anesthesia alone are recognized (113,114). 
Ethyl ether stimulates the adrenal cortex, as shown by the increase in peripheral blood levels 
of corticosteroids in man (66, 163). Ethyl ether is the strongest stimulant of adrenocortical 
activity among available anesthetic agents (113,115). Ethyl ether anesthesia increases plasma 
catecholamines in man (21, 120). The increase is mainly due to a rise in plasma noradrenalin 
(113). The increase in plasma catecholamines leads to a mobilization of glycogen from both 
the liver and muscle tissue, and marked rise in blood sugar follows (35).
The levels of thyroid stimulating hormone (TSH) do not change appreciably during ethyl ether 
anesthesia. The levels of thyroxine increase significantly, whereas the triiodothyronine levels 
decrease in humans during ethyl ether anesthesia (97).
Plasma aldosterone levels and plasma renin activity increase during ethyl ether anesthesia (15, 
115). The plasma antidiuretic hormone levels also increase significantly after the induction 
of anesthesia with ethyl ether (97).
Ethyl ether anesthesia caused a significant decrease in serum calcium levels in 30 patients 
undergoing various routine surgical operations. Serum calcium returned to near normal levels 
after 24 hr. The mechanism behind this effect is not known (62).
6.11.2 Laboratory Animals
Ethyl ether anesthesia administered by placing rats in an ether-saturated jar and then main­
tained with a nose cone for 3 min caused a significant increase in plasma adrenocorticotrophic 
hormone (ACTH) levels. Ethyl ether failed to raise the plasma ACTH levels of rats in which 
an antero-lateral hypothalamic cut and adrenalectomy had been performed 7 to 8 days 
previously, and plasma ACTH was also unchanged in rats exposed to ethyl ether 2 hr after an 
antero-lateral cut. The results are interpreted as evidence that intact neural pathways entering 
the medial basal hypothalamus from the antero-lateral direction are necessary for the ACTH- 
releasing action of ethyl ether stress (78).
Plasma corticotropin releasing hormone (CRH), arginine vasopressin (AVP), oxytocin (OXY) 
and ACTH levels rose to approximately twice the level of control rats 2 min after the onset of
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a 1-min exposure to ethyl ether. Plasma CRH rose further 5 min after the onset of ethyl ether 
stress, while plasma A VP and OXY returned to the baseline level at 5 min (67).
Ethyl ether anesthesia did not affect the mean concentrations or dissociation constants for rat 
uterine estrogen or progesterone receptors (173). No difference in plasma thyroxine levels 
were found between control rats and rats exposed to ethyl ether inhalation for 2 min (89). 
Ethyl ether anesthesia in rats increased the concentration of plasma beta-endorphin-like 
immunoreactivity, probably of pituitary origin. This increase was not associated with sig­
nificant changes in pituitary or brainstem beta-endorphin content (121).
7 IMMUNE SYSTEM
After treatment of human sera with ethyl ether, there were no significant changes in im­
munoglobulin levels, whereas the complement activity was lost (142).
The effects on lymphocyte responses were studied in seven patients undergoing surgery under 
anesthesia with ethyl ether + N2O + O2 . The variables studied were the leukocyte and 
differential count, the T- and B-lymphocyte count, and lymphocyte transformation by different 
substances. There were no significant changes in the total lymphocyte or in the T- and 
B-lymphocyte counts, whereas the mitogen and purified protein derivate of tuberculin (PPD) 
responses showed a fall in lymphocyte transformation. The authors concluded that operative 
trauma rather than anesthesia determined the decrease in lymphocytic responses (130).
The effects of anesthetic agents, surgery, and blood loss during operation on the immune 
system was studied in 18 cancer patients undergoing elective operation for tumor removal. A 
suppression of the patients peripheral blood lymphocyte blastogenic responses was seen with 
both ethyl ether and halothane anesthesia, though more significantly with ethyl ether. The 
B-cell responses were more affected by ethyl ether than the T-cell responses. The volume of 
blood lost during surgery was also correlated with the degree of immunosuppression. The 
immunosuppression induced by anesthesia and surgery persisted for at least 7 days (74).
The effects of three different anesthetics (ethyl ether, Avertin and Ketamine) on the activity 
of splenic natural killer (NK) cells was investigated in mice. Natural killer cells are a 
subpopulation of large granular lymphocytes displaying spontaneous cytotoxicity against 
tumor cells, virus-infected cells, and some microbial pathogens. All three anesthetics caused 
a significant inhibition of the induction of NK activity by Poly I:C, but had no effect on baseline 
NK. Since all anesthetics had the same effect, this effect was probably due to the state of 
general anesthesia rather than to the pharmacological properties of the anesthetics (95).
8 MUTAGENICITY, GENOTOXICITY
In an early study, Morgan (102) showed that ethyl ether delivered by inhalation for about 11 
days, did not produce mutations in Drosophila ampelophila.
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Several commonly used volatile anesthetics were screened for mutagenicity in the Salmonella/ 
rat liver microsomal assay system. Ethyl ether was reported to be not mutagenic (165). When 
the genotoxic activity and potency of 135 compounds were investigated in the Ames reversion 
test and in a bacterial DNA-repair test, there was no evidence of genotoxic activity for ethyl 
ether (38).
9 CARCINOGENICITY
Fluck et al. (46) used differential growth inhibition of two E. coli cultures as a rapid screening 
technique for chemical carcinogens. Ethyl ether from a freshly opened can yielded negative 
results, whereas a positive response was obtained with ethyl ether that had been exposed to 
air. The latter result was considered as false positive, however, due to the formation of 
peroxide oxidants.
White et al. (169) investigated inhaled anesthetics with the sister chromatid exchange (SCE) 
technique, a rapid assay of mutagenic-carcinogenic potential. When the cell cultures are 
exposed to mutagen-carcinogens, the frequency of sister chromatid exchanges increase. 
Exposure for 1 hr to 1.97 vol% (19,700 ppm) ethyl ether did not increase SCE values.
10 REPRODUCTIVE TOXICITY
In an epidemiologic study of Russian anesthesiologists, Vaisman (158) reported that 18 of 31 
pregnancies among 110 female anesthesiologists, aged 24-38 years, ended in spontaneous 
abortions. In addition, two premature births were reported and in one case the child had 
congenital malformations. The anesthesiologists with abnormal pregnancies had exposures 
of 25 hr/week or more while those with normal pregnancies had less than 15 hr/week exposure. 
Ninety-eight percent of the anesthesiologists reported use of ethyl ether, 59% nitrous oxide, 
28% halothane and 21% other agents. Concentration levels were not presented. Since the 
anesthesiologists were exposed to several different anesthetics, no conclusion can be drawn 
about the reproductive toxicity of ethyl ether from this study.
The epididymal spermatozoa of mice were examined for morphologic abnormalities following 
exposure to or near one-tenth of the minimum anesthetic concentration and greater concentra­
tions of several general anesthetics including ethyl ether. The mice were exposed to 1.6 or
0.32 vol% (49,280 or 9,856 mg/m3) ethyl ether 4 hr/day for five consecutive days. There was 
no significant increase in the level of morphologically abnormal spermatozoa after exposure 
to ethyl ether (88).
According to Smith et al. (135), ethyl ether might have teratogenic effects in the chick embryo. 
Fertile eggs of white leghorn chickens were studied. Exposures were carried out in glass 
chambers during heating with infrared light. Ethyl ether was vaporized by a Copper Kettle 
vaporizer, and the carrier gas was compressed air. The concentration of ethyl ether varied 
from 9 to 30 vol% (277,200 to 924,000 mg/m3) and the duration of the exposure was 5 
to 6 hr. There was an increasing sensitivity to lethal effects of ethyl ether in the first 4 days
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of incubation. The elevation in rate of abnormal survivors after exposure to ethyl ether was 
statistically significant in six groups of experiments on days 3 and 4. The death rate was very 
high, however. For example, exposure to 20 vol% ethyl ether for 6 hr on day 3 caused 96.1 % 
dead embryos. The type of anomalies produced by ethyl ether exposure was the same as that 
induced by any generally toxic agent given at the same stage o f development.
11 DOSE-EFFECT AND DOSE-RESPONSE RELATIONSHIPS
11.1 Observations in Man
11.1.1 Inhalation
Odor detection and odor recognition levels have been investigated for ethyl ether (140). The 
values between investigations differ greatly due to different methods for making these 
determinations and because scales used in these evalutions are not standardized (31).
Ethyl ether is used as an anesthetic in clinical medicine. The anesthetic may be given on an 
open mask or by means of a vaporizer. For induction of anesthesia, concentrations of 10 to 
15 vol% (308,000 to 462,000 mg/m3) in air are needed. Light anesthesia is maintained at 
approximately 3 to 5 vol% (92,400 to 154,000 mg/m3), but deep anesthesia may require 
concentrations up to 10 vol% (308,000 mg/m3) or more (162). The minimum alveolar 
anesthetic concentration is defined as that concentration o f anesthetic in alveolar or 
end-expired gas that is present when 50% of the subjects do not respond to a surgical stimulus, 
usually a skin incision. For ethyl ether, the minimum alveolar anesthetic concentration is
1.92% (expressed as partial pressure of agent in alveolar space divided by standard total 
atmospheric pressure x 100) (25).
The depth of ethyl ether anesthesia has been divided into four stages by Guedel (59) who did 
an exhaustive study of open ether anesthetics. As the depth of anesthesia increases, the 
respiratory pattern changes, more reflexes become suppressed, and characteristic changes in 
the size of the pupil can be seen. This slow progression of changes has made it possible to 
correlate the alterations in reflex activity to four stages of ethyl ether anesthesia (Table 1). The 
stages are: I-stage of analgesia; E-stage of delirium; IH-stage of surgical anesthesia; and 
IV-stage of medullary compression. State El, the level of surgical anesthesia, can be further 
subdivided into four planes. The approximate blood and alveolar levels of ethyl ether in 
relation to depth of anesthesia have been determined (Table 2).
Nelson et al. (106) studied the irritating and unpleasant effects on humans of some common 
solvent vapors. An average of 10 persons of mixed sexes were exposed to a given concentra­
tion of solvent vapor for 3-5 min in a 1,200 cubic foot gas cabinet. Each individual classified 
the effect of the vapor on eyes, nose, and throat as no reaction, slightly irritating, or very 
irritating. Each person was asked if he believed he could work in the atmosphere for an 8-hr 
day. The concentration of vapor which the majority rejected as a working atmosphere
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Table 2.—Approximate blood and alveolar levels o f ethyl ether 
in relation to depth o f anesthesia*
Stage
Blood level 
(mg/1)
Alveolar concentration 
mg/m3 vol%
Stage I 100-400 8,747-35,112 0.284-1.14
Stage II 400-800 35,112-69,916 1.14-2.27
Stage m
Plane I 800-1,100 69,916-96,096 2.27-3.12
Plane II 1,100-1,200 96,096-105,028 3.12-3.41
Plane III 1,200-1,300 105,028-113,652 3.41-3.69
Plane IV 1,300-1,400 113,652-122,584 3.69-3.98
Stage IV 1,400-1,800 122,584-157,388 3.98-5.11
’Adapted from reference 35.
was termed objectionable. For ethyl ether, complaints of nasal irritation started at 200 ppm 
(616 mg/m3), and 300 ppm (924 mg/m3) was objectionable as a working atmosphere.
According to Cook (36), industrial exposure at 500 to 1,000 ppm (1,540 to 3,080 mg/m3) did 
not cause any demonstrable injury to health, but a limit of 500 ppm seemed justifiable to avoid 
irritation and complaint. Amor (5) also considered a concentration of ethyl ether in the 
atmosphere greater than 500 ppm (1,540 mg/m3) as indicative of unsatisfactory conditions. 
He listed 2,000 ppm (6,160 mg/m3) as the concentration which may lead to symptoms of illness 
(not specified) if exposure continues for more than a short time.
Ethyl ether concentrations of 2,000 to 3,000 ppm (6,160 to 9,240 mg/m3) may occur in the air 
during the manufacture of smokeless powder and has been reported to result in an occasional 
slight intoxication (69). The inhalation of ethyl ether at a concentration of 2,000 ppm 
(6,160 mg/m3), if continued to equilibrium, has been calculated to result in the absorption of 
some 6.25 g of ethyl ether and a blood concentration of 90 mg/1. According to Henderson and 
Haggard (69), inhalation of ethyl ether at these concentrations would probably induce dizziness 
in some individuals with an increased risk for industrial accidents.
Concentrations above 3,000 ppm (9,240 mg/m3) as high as 7,000 ppm (21,560 mg/m3) have 
been breathed by some workers for variable periods of time. It has been claimed that these 
concentrations do not cause any physiological or clinical signs of injury, or any increase in 
the incidence of industrial accidents (7).
According to Amor (5), inhalation of ethyl ether at a concentration of 8,000 ppm 
(24,640 mg/m3) for 1 hr will give rise to severe toxic effects (toxic effects not specified).
A concentration of 35,000 ppm (107,800 mg/m3) of ethyl ether usually produces unconscious­
ness in 30 to 40 min (69).
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Postmortem blood ethyl ether concentrations of 2,880-3,750 mg/1 were reported in two 
surgical patients who died within 2.5 hr after cessation of ethyl ether administration (30).
11.1.2 Ingestion
Ethyl ether is irritating to the mucous membranes, and humans therefore usually refrain from 
drinking it. The “ether habit” by ingestion is well known, however. The symptoms are said 
to be similar to those of chronic alcoholism but they occur earlier (28).
The lethal dose of ethyl ether after peroral intake has been estimated to about 30 ml (21.4 g) 
(17, 99). Geldmacher-v Mallinckrodt (52) reported that the lethal dose of ethyl ether after 
peroral intake was 30-50 g. A 1-year-old child who died of peroral intake of an unknown 
amount of ethyl ether had a postmortem ethyl ether concentration in blood o f2,360 mg/1 (123).
11.2 Observations in Animals
11.2.1 Inhalation
Effects of a 35-day continuous exposure to ethyl ether in concentrations of 0.1 or 1.0 vol% 
(3,080 to 30,800 mg/m3) were investigated in young mice, rats, and guinea pigs which were 
in a phase of rapid body growth. Ethyl ether had a negligible effect on rat or mouse weight 
gain but produced a statistically significant weight loss in guinea pigs at the higher concentra­
tion. Livers from mice and guinea pigs treated with 1.0 vol% (30,800 mg/m3) ethyl ether 
showed only slight increases in lesions compared to controls, whereas no increase in lesions 
were seen in rats. No consistent injury to any other organ than the liver was observed. The 
higher dose of ethyl ether was reported to be lethal to mice and guinea pigs, but not to rats. A 
draw-back with this study is that the authors were unable to explain the mechanism behind 
ethyl ether lethality. The mortality was not related to changes in blood or any tissue examined, 
including the bone marrow. The animals showed enlargement of the liver, but how this was 
related to ethyl ether lethality was unclear (143).
The results obtained for the concentration of the ethyl-ether-air mixture required for the 
maintenance of anesthesia, and for the lethal concentration of inhaled ethyl ether varies 
between different species and also between different investigators for the same species. This 
variation can partly be explained by differences in induction mixtures and duration of the 
anesthesia (124). The results o f various investigations o f inhalation toxicity for ethyl 
ether in animals is presented in Table 3. The lethal concentration for mice during a 
continuous exposure for 97 min was 133,400 mg/m3 or 4.4 vol% (86). Molitor (100) 
obtained a similar result for the mouse and calculated the LC50 for a continuous exposure 
for 3 hr to be 129,500 mg/m3 or 4.2 vol%. Swann et al. (148) reported that 3.2 vol% 
(98,560 mg/m3) of diethyl ether produced excitation and anesthesia in mice. At 6.4 vol% 
(197,120 mg/m3) deep anesthesia was produced and respiratory arrest occurred at 12.8 vol% 
(394,240 mg/m3). When rapid induction and short duration of anesthesia was used, the 
concentration required to produce respiratory arrest in mice was found to be 18 vol% 
(554,400 mg/m3) (103).
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Table 3.—Inhalation toxicity of ethyl ether
Species
Cone
(mg/m3)
Exposure
(min) Effect Reference
Mouse 554,400 10 Respiratory arrest (103)
Mouse 394,240 5 Irregular respiration 
respiratory arrest in 
1/4
(148)
Mouse 197,120 5 Deep anesthesia (148)
Mouse (male, strain 
C57BL/6)
184,800 90 LCso (85)
Mouse 184,800 10 Surgical anesthesia (103)
Mouse 133,400 67-120 7/10 died (86)
Mouse 129,500 180 LC50 (100)
Mouse 98,560 5 Slight excitation and 
irritation followed 
by anesthesia
(148)
Mouse (male, strain 
C3H/He)
95,480 90 LC50 (85)
Dog 206,360
-246,400
20-120 Respiratory arrest (124)
Lethal concentrations of ethyl ether in air for the rat was 6.4 vol% (197,120 mg/m3) whereas 
the values for the rabbit and dog were 10.6 vol% (326,480 mg/m3) and 7.6-19.25 vol% 
(234,080-592,900 mg/m3), respectively (133).
Robbins (124) studied the responses in dogs to different concentrations of inhaled ethyl ether. 
Respiratory failure occurred with air mixtures of 6.7 to 8 vol% (206,360 to 246,400 mg/m3) 
and a blood concentration of 1,700 to 1,900 mg/1 (average for 20 dogs 1,870 mg/1). The 
experiments lasted from 20 min to 2 hr. The knee jerk was abolished at a blood ethyl ether 
concentration of 1,430 mg/1 and the lid reflex at 1,500 mg/1.
The susceptibility to inhaled ethyl ether in rats is influenced by the age of the animal. The 
median time to death (L T 50) for neonates was 5 to 6.5 times greater than for adult rats. At the 
respective L T 50 values, the mean concentration of diethyl ether in blood was 2.5 to 3 times 
greater in neonatal rats than in adult rats (132).
11.2.2 Ingestion
The oral LD50 in a 2-week-old, young adult (body weight 80-160 g) and adult (body 
weight 300-470 g) rat, were reported to be 2.3, 2.4, and 1.7 ml/kg b.w., respectively (83). 
Smyth et al. (138) reported a single peroral LD50 for rats of 3.56 ml/kg b.w.
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12 RESEARCH NEEDS
Most of the investigations on the effects of ethyl ether on humans concern its use as an 
anesthetic agent. More information is needed about the effects on humans o f industrial 
exposure to low concentrations of ethyl ether vapor, especially effects on the upper respiratory 
passages and the CNS. Additional studies on the effects of long-term inhalation of ethyl ether 
are needed to evaluate chronic toxicity. There is also a need for more studies on possible 
teratogenic, carcinogenic, and genotoxic effects of ethyl ether exposure. The effects on the 
kidneys of long-term industrial exposure to ethyl ether in air should be reevaluated. In the 
older literature, a few case reports describe the development o f nephritis but this effect has 
later been questioned.
13 DISCUSSION AND EVALUATION
The principal exposure routes to ethyl ether in the occupational situation are inhalation and 
skin contact. Inhalation of ethyl ether vapor causes irritation to the mucous membranes of the 
nose and respiratory passages. Liquid ethyl ether is a mild skin irritant due to its defatting 
properties and repeated exposure may cause dermatitis. Inhalation of ethyl ether has effects 
on the CNS. Acute exposure to high concentrations of ethyl ether vapor produces initial 
excitement followed by narcosis and respiratory depression. Long-term exposure to low 
concentrations of ethyl ether vapor in industry has been reported to cause various symptoms 
from the CNS such as sleepiness, dizziness, excitation, headache, and psychic disturbances. 
Ethyl ether causes conjunctival irritation in either liquid form or high concentrations in the 
air. Ethyl ether anesthesia causes an increase in plasma catecholamines which leads to a 
mobilization of glycogen from the liver and muscle tissue and a rise in blood sugar.
Investigations of possible mutagenic or carcinogenic effects of ethyl ether have shown negative 
results. The number of these studies is limited, however.
The irritating effects of ethyl ether vapor on the upper respiratory passages is the critical effect 
which should be taken into consideration in the establishment of an occupational exposure 
limit for ethyl ether. Complaints of nasal irritation have been reported to start at 200 ppm 
(616 mg/m3) of ethyl ether in air. The effects of low concentrations of ethyl ether vapor on 
the CNS should also be given attention. During the manufacture of smokeless powder, 
concentrations of 2,000 to 3,000 ppm (6,160 to 9,240 mg/m3) may occur. These concentra­
tions have been reported to cause dizziness in some individuals with increased likelihood of 
industrial accidents.
The majority of inhaled ethyl ether (87-90%) is excreted unchanged through the lungs. A 
fraction of ethyl ether is metabolized to ethanol and acetaldehyde by an inducible hepatic 
microsomal enyme system. Ethanol and acetaldehyde are oxidized to acetate and the acetate 
then enters the 2-carbon pool of intermediary metabolism.
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14 SUMMARY
Björn Arvidson: Ethyl ether. Nordic Expert Group for Documentation of Occupational 
Exposure Limits, NIOH and NIOSH Basis for an Occupational Health Standard.
A survey of the literature relevant to the discussion of occupational exposure limits for ethyl 
ether is presented. Ethyl ether has a wide range of uses in the chemical industry. It is used 
mainly as a solvent and as an extraction medium. Ethyl ether has been used as an inhalation 
anesthetic for surgery but to a large extent has now been replaced by more modem anesthetics. 
The.acute and chronic toxicity of ethyl ether is low. The principal exposure routes to ethyl 
ether in the occupational situation are inhalation and skin contact. The critical effect of ethyl 
ether is irritation of the upper respiratory passages. Long-term exposure to low concentrations 
of ethyl ether in air may give symptoms from the CNS. Symptoms that have been reported 
are sleepiness, dizziness, irritability, headache, and psychic disturbances. Ethyl ether is a mild 
skin irritant, especially after repeated exposures.
Key words: Ethyl ether, occupational exposure limits, solvents, anesthetics.
15 SAMMANFATTNING
Björn Arvidson: Etyleter. Nordiska Expertgruppen för Gränsvärdesdokumentation, NIOH and 
NIOSH Basis for an Occupational Health Standard.
En litteraturgenomgang har gjorts for att fa fram ett underlag till diskussionen kring ett 
hygieniskt gränsvärde för etyleter. Inom den kemiska industrin används etyleter främst som 
ett lösningsmedel och ett extraktionsmedel. Etyleter har tidigare använts som narkosmedel i 
samband med kirurgiska operationer men har nu i stor utsträckning ersatts av modemare 
medel. Den akuta och kroniska toxiciteten for etyleter är lag. Vid industriell använding är 
exponeringsvägama främst inhalation och hudkontakt. Den kritiska effekten för etyleter är 
irritation av slemhinnor inom de övre luftvägama. Längre tids exponering för läga halter av 
etyleter i luft kan ge symtom fran det centrala nervsystemet i form av trötthet, yrsel, irritabilitet, 
huvudvärk, och psykiska stömingar. Etyleter i flytande form ger uttorkning av huden, speciellt 
efter upprepad kontakt.
Nyckelord: Etyleter, hygieniskt gränsvärde, anestesimedel, lösningsmedel.
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